Big Money Sentiment decreased to 1 in 2018 Q4. It has change of 0.11, from 2018Q3’s 1.11. The ratio worsened due to Esperion Therapeutics, Inc. positioning: 22 sold and 40 reduced. 23 funds acquired stakes and 39 increased stakes. Investors holded 24.60 million in 2018Q3 but now own 24.06 million shares or 2.18% less.
7,681 were reported by Trexquant Limited Partnership. Ubs Asset Mgmt Americas Inc invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Wisconsin-based Northwestern Mutual Wealth has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Amundi Pioneer Asset Management holds 0.01% of its capital in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 274,061 shs. Wells Fargo And Comm Mn holds 0% or 15,948 shs. Victory Mngmt Inc has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Hightower Llc reported 0.01% stake. Paloma Ptnrs Com invested in 4,500 shs or 0.01% of the stock. Charles Schwab Mngmt owns 131,973 shs. 2.49M are held by Pentwater Cap Mngmt Limited Partnership. New York-based Millennium Ltd Liability Co has invested 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Meeder Asset Mngmt holds 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 98 shs. Ameriprise Fincl Incorporated accumulated 25,565 shs. Goldman Sachs Inc reported 0% of its capital in Esperion Therapeutics, Inc. (NASDAQ:ESPR). California State Teachers Retirement Systems owns 35,846 shs or 0% of their US capital.

Esperion Therapeutics, Inc. (NASDAQ:ESPR)’s quarterly earnings will be reported on May, 1., Faxor reports. Last year’s earnings per share was $-1.73, while now analysts expect change of 143.93 % up from current $0.76 earnings per share. If reported the P/E will be 13.48 with $20.39 million profit. After $-2.24 EPS report previous quarter, Wall Street now predicts -133.93 % EPS growth of Esperion Therapeutics, Inc.. ESPR hit $40.97 during the last trading session after $1.16 change.Currently Esperion Therapeutics, Inc. is downtrending after 39.96% change in last March 28, 2018. ESPR has also 409,554 shares volume. ESPR underperformed by 44.33% the S&P 500.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

A total of 8 analysts rate Esperion Therapeutics (NASDAQ:ESPR) as follows: 4 “Buy”, 3 “Hold” and 1 “Sell”. Тherefore 50% are bullish. (NASDAQ:ESPR) has 8 ratings reports on Mar 28, 2019 according to StockzIntelligence. On Thursday, March 14 the stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Hold” rating given by Chardan Capital Markets. On Tuesday, March 5 the company was maintained by Stifel Nicolaus. On Wednesday, March 13 the rating was upgraded by JP Morgan to “Neutral”. On Friday, March 1 the firm has “Buy” rating given by Cowen & Co. The stock rating was upgraded by J.P. Morgan to “Hold” on Wednesday, March 13. The company rating was maintained by Northland Capital on Friday, March 1.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol .The firm is valued at $1.10 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study.Currently it has negative earnings.

For more Esperion Therapeutics, Inc. (NASDAQ:ESPR) news published recently go to: Nasdaq.com, Globenewswire.com, Globenewswire.com, Nasdaq.com or Benzinga.com. The titles are as follows: “Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4 – Nasdaq” published on March 01, 2019, “Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions – GlobeNewswire” on March 18, 2019, “Esperion to Participate in Upcoming Investor Conferences – GlobeNewswire” with a publish date: March 04, 2019, “Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions – Nasdaq” and the last “Benzinga’s Top Upgrades, Downgrades For March 13, 2019 – Benzinga” with publication date: March 13, 2019.